19 December 2023

Q123, also known as VUN701, a single domain antibody binding human atypical chemokine receptor 3 (aka CXCR7) with nanomolar affinity, is now available for research use. 

Generated and characterized by Vladimir Bobkov and Martine Smit’s lab at the VU, its effect on receptor conformation was then investigated with Brian Volkman’s lab at Medical College of Wisconsin. Together, this molecule proved to be a neutral antagonist with nanomolar potencies. The work was published in this Science paper last year.